Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data

References

• Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136–41.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649–62.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039–52.
   PubMed Web of Science ®Google Scholar
• Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis. 2015;74(4):661–7.
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66(10):1311–5.
   PubMed Web of Science ®Google Scholar
• Neogi T, Hunter DJ, Chaisson CE, Allensworth-Davies D, Zhang Y. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006;33(1):104–9.
   PubMed Web of Science ®Google Scholar
• Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321–5.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. The Guideline Revising Committee of the Japanese Society of gout and nucleic acid metabolism. Essence of the revised guideline for the management of hyperuricemia and gout. Japan Med Assoc J. 2012;55(4):324–9.
   PubMedGoogle Scholar
• Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431–46.
   PubMed Web of Science ®Google Scholar
• Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
   PubMed Web of Science ®Google Scholar
• Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632–8.
   PubMed Web of Science ®Google Scholar
• Pandya BJ, Riedel AA, Swindle JP, Becker LK, Hariri A, Dabbous O, et al. Relationship between physician specialty and allopurinol prescribing patterns: A study of patients with gout in managed care settings. Curr Med Res Opin. 2011;27(4):737–44.
   PubMed Web of Science ®Google Scholar
• Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P. Achieving serum urate goal: A comparative effectiveness study between allopurinol and febuxostat. Postgrad Med. 2014;126(2):65–75.
   PubMed Web of Science ®Google Scholar
• Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology. 2011;50(5):973–81.
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, et al. Effects of febuxostat in early gout: A randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(12):2386–95.
   PubMed Web of Science ®Google Scholar
• Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol. 2011;23(2):156–60.
   PubMed Web of Science ®Google Scholar
• Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, et al. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: Phase 3 clinical study. J Clin Rheumatol. 2011;17(2):S13–S8.
   PubMedGoogle Scholar
• Becker MA, Schumacher HR, Jr., Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450–61.
   PubMed Web of Science ®Google Scholar
• Kimura S, Sato T, Ikeda S, Noda M, Nakayama T. Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20(5):413–9.
   PubMed Web of Science ®Google Scholar
• Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol. 2019;29(5):880–4.
   PubMed Web of Science ®Google Scholar
• Kumar AUA, Browne LD, Li X, Adeeb F, Perez-Ruiz F, Fraser AD, et al. Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study. PLoS One. 2018;13(5):e0198197.
   PubMed Web of Science ®Google Scholar
• Liu R, Han C, Wu D, Xia X, Gu J, Guan H, et al. Prevalence of hyperuricemia and gout in mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int. 2015;2015:762820.
   PubMed Web of Science ®Google Scholar
• Hosoya T, Sasaki T, Ohashi T. Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: A randomized, double-blinded, controlled phase 2b study. Clin Rheumatol. 2017;36(3):649–56.
   PubMed Web of Science ®Google Scholar
• Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689–702.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: Results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270–6.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Kamatani N, Kashiwazaki S. Comparative study of allopurinol and benzbromarone on the kinetics of uric acid metabolism. Hyperuricemia and Gout 1994;2:103–11.
   Google Scholar
• Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: A randomized trial. Am J Kidney Dis. 2018;72(6):798–810.
   PubMed Web of Science ®Google Scholar
• Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: A retrospective medical claims-based analysis. BMJ Open. 2015;5(6):e007214.
   PubMed Web of Science ®Google Scholar